Blue-grey hyperpigmentation in acne after vandetanib therapy and doxycycline use: A case report

Vandetanib is an oral tyrosine kinase inhibitor with cutaneous adverse effects that include the development of acne. We present a patient who underwent vandetanib therapy for stage IV medullary thyroid cancer in conjunction with the use of doxycycline for acne that developed. After vandetanib use, b...

Full description

Saved in:
Bibliographic Details
Published in:SAGE open medical case reports 2022-03, Vol.10, p.2050313X221086316
Main Authors: Perlmutter, Jonah W, Cogan, Rachel C, Wiseman, Marni C
Format: Article
Language:English
Subjects:
Acne
Antibiotics
Case reports
Drug therapy
JCMS Case Report
Thyroid cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vandetanib is an oral tyrosine kinase inhibitor with cutaneous adverse effects that include the development of acne. We present a patient who underwent vandetanib therapy for stage IV medullary thyroid cancer in conjunction with the use of doxycycline for acne that developed. After vandetanib use, blue-grey pigmentation developed in the acne on his face, chest, back, and arms, which darkened after the use of doxycycline. We review the literature to report that this blue-grey hyperpigmentation was likely vandetanib-induced but may have been the result of both drugs being used in combination.
ISSN:2050-313X
2050-313X
DOI:10.1177/2050313X221086316